Trubion Wins Genentech, Biogen Patent Case
Luke Timmerman6/3/10
Seattle-based Trubion Pharmaceuticals (NASDAQ: TRBN), the developer of targeted therapies for cancer and autoimmune diseases, said today it has won a patent dispute against Genentech and Biogen Idec. The dispute centers on targeted therapies designed to block a marker on cells, CD20, which is currently hit by Genentech and Biogen Idec’s rituximab (Rituxan). Trubion, which has developed its own CD-20 blocker, challenged a European patent held by Genentech and were successfully able to revoke it in September 2008. That ruling has now been upheld by a European appeals board, which had the final decision in the matter, Trubion said in a statement.
Luke Timmerman is the National Biotech Editor of Xconomy, and the Editor of Xconomy Seattle. E-mail him at ltimmerman@xconomy.com or follow him on Twitter at twitter.com/ldtimmerman.
